Standout Papers

mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activat... 2002 2026 2010 2018 2.0k
  1. mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt (2006)
    Kathryn O’Reilly, Qing‐Bai She et al. Cancer Research
  2. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion (2012)
    Ravid Straussman, Teppei Morikawa et al. Nature
  3. BRAF mutation predicts sensitivity to MEK inhibition (2005)
    David B. Solit, Levi A. Garraway et al. Nature
  4. Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy (2017)
    Diego Chowell, Luc G.T. Morris et al. Science
  5. Akt Forms an Intracellular Complex with Heat Shock Protein 90 (Hsp90) and Cdc37 and Is Destabilized by Inhibitors of Hsp90 Function (2002)
    Andrea Basso, David B. Solit et al. Journal of Biological Chemistry
  6. Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes (2017)
    Catherine C. Coombs, Ahmet Zehir et al. Cell stem cell
  7. Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity (2015)
    Matthew T. Chang, Saurabh Asthana et al. Nature Biotechnology
  8. Genome Sequencing Identifies a Basis for Everolimus Sensitivity (2012)
    Gopa Iyer, Aphrothiti J. Hanrahan et al. Science
  9. Tumor adaptation and resistance to RAF inhibitors (2013)
    Piro Lito, Neal Rosen et al. Nature Medicine
  10. Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers (2018)
    Min Yuen Teo, Kenneth Seier et al. Journal of Clinical Oncology
  11. Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention (2018)
    Maeve A. Lowery, Ryan Ptashkin et al. Clinical Cancer Research
  12. Genome doubling shapes the evolution and prognosis of advanced cancers (2018)
    Craig M. Bielski, Ahmet Zehir et al. Nature Genetics
  13. BRAF — a tumour-agnostic drug target with lineage-specific dependencies (2024)
    Aphrothiti J. Hanrahan, Neal Rosen et al. Nature Reviews Clinical Oncology

Immediate Impact

46 from Science/Nature 118 standout
Sub-graph 1 of 15

Citing Papers

Cancer biomarkers: Emerging trends and clinical implications for personalized treatment
2024 Standout
Fibroblasts in cancer: Unity in heterogeneity
2023 Standout
19 intermediate papers

Works of David B. Solit being referenced

Tumor adaptation and resistance to RAF inhibitors
2013 Standout
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
2012 StandoutNature
and 4 more

Author Peers

Author Last Decade Papers Cites
David B. Solit 10407 15386 5456 358 25.6k
Grant A. McArthur 14701 14988 5248 388 26.3k
P. Andrew Futreal 7666 16483 4826 287 27.3k
Neal Rosen 12021 24403 5578 255 34.3k
Olli Kallioniemi 9579 19874 7275 419 35.7k
Brian Druker 10862 17055 6248 597 54.0k
Jeffrey A. Sosman 15916 15337 8198 343 28.0k
Martin Gore 14140 12791 8895 377 29.0k
Levi A. Garraway 6935 14619 3808 172 22.1k
Michael R. Stratton 10038 22968 4702 212 38.5k
Nikolaus Schultz 11479 24300 9694 224 38.0k

All Works

Loading papers...

Rankless by CCL
2026